The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature.

The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature.

Item
http://www.wikidata.org/entity/Q34000557
Biomarkers for lysosomal storage disorders: identification and application as exemplified by chitotriosidase in Gaucher disease.Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcomeMigalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients.Human breast cancer and lymph node metastases express Gb3 and can be targeted by STxB-vectorized chemotherapeutic compounds.Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies.Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics.Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing.Sequential One-Pot Multienzyme Chemoenzymatic Synthesis of Glycosphingolipid Glycans.Elevated globotriaosylsphingosine is a hallmark of Fabry disease.Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma.Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies.Effects of enzyme replacement therapy in Fabry disease--a comprehensive review of the medical literature.Fabry disease, enzyme replacement therapy and the significance of antibody responses.Fabry's disease: an example of cardiorenal syndrome type 5.Therapeutic goals in the treatment of Fabry disease.Fabry disease
P2860

The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature.

Item
http://www.wikidata.org/entity/Q34000557
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
The role of ceramide trihexosi ...... e: a review of the literature.
@ast
The role of ceramide trihexosi ...... e: a review of the literature.
@en
The role of ceramide trihexoside
@nl
type
label
The role of ceramide trihexosi ...... e: a review of the literature.
@ast
The role of ceramide trihexosi ...... e: a review of the literature.
@en
The role of ceramide trihexoside
@nl
prefLabel
The role of ceramide trihexosi ...... e: a review of the literature.
@ast
The role of ceramide trihexosi ...... e: a review of the literature.
@en
The role of ceramide trihexoside
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
The role of ceramide trihexosi ...... e: a review of the literature.
@en
P2093
P304
P31
P356
10.2174/187152506778520718
P433
P478
P577
P698